Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00853762
Registration number
NCT00853762
Ethics application status
Date submitted
26/02/2009
Date registered
2/03/2009
Date last updated
20/03/2017
Titles & IDs
Public title
Atacicept in Multiple Sclerosis Extension Study, Phase II
Query!
Scientific title
An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)
Query!
Secondary ID [1]
0
0
28851
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ATAMS ext
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsing Multiple Sclerosis
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atacicept 25 mg
Treatment: Drugs - Atacicept 75 mg
Treatment: Drugs - Atacicept 150 mg
Treatment: Drugs - Atacicept 150 mg
Experimental: Atacicept 25 mg (With Loading) -
Experimental: Atacicept 75 mg (With Loading) -
Experimental: Atacicept 150 mg (With Loading) -
Experimental: Atacicept 150 mg (Without Loading) -
Treatment: Drugs: Atacicept 25 mg
Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Treatment: Drugs: Atacicept 75 mg
Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Treatment: Drugs: Atacicept 150 mg
Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Treatment: Drugs: Atacicept 150 mg
Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity
Query!
Assessment method [1]
0
0
TEAEs were defined as AEs with a start date after or on the date of the first DB treatment injection in ATAMS Extension and that occurred anytime after treatment discontinuation, or up to the day before first Rebif® rescue medication injection in ATAMS Extension. A serious TEAE was an AE that resulted in any of the following: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAE severity was graded as per Qualitative Toxicity Scale. Local injection site reactions (injection site: pain, redness, itching and swelling) throughout ATAMS Extension, starting after the first trial medication administration. If the subject experienced 1 or more of the above injection site symptoms, these were reported with the AE verbatim term "injection site reaction". For all randomized subjects, there was an option of rescue treatment with Rebif® for 1 year beginning with the first injection of Rebif®).
Query!
Timepoint [1]
0
0
From the first dose of study drug administration up to Week 24
Query!
Primary outcome [2]
0
0
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Query!
Assessment method [2]
0
0
Blood pressure (systolic and diastolic) was measured after at least 3 minutes resting, with the subject in the seated position.
Query!
Timepoint [2]
0
0
Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Query!
Primary outcome [3]
0
0
Change From Baseline in Vital Signs: Pulse Rate
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Query!
Primary outcome [4]
0
0
Change From Baseline in Vital Signs: Temperature
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Query!
Primary outcome [5]
0
0
Change From Baseline in Electrocardiogram (ECGs)
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline, Week 12 and 36
Query!
Primary outcome [6]
0
0
Number of Subjects With Worsened Post Baseline Shift in Immunoglobulin A (IgA), IgG and IgM Levels
Query!
Assessment method [6]
0
0
Number of subjects with shifts from normal Grade (Grade 0) at Baseline to worse value at post-baseline (Grade 1 to Grade 4) according to the following criteria: IgA Grade 0: greater than or equal to (\>=) lower limit normal (LLN) 0.7 gram per liter (g/L); Grade 1: less than (\<) LLN - 0.5 g/L, Grade 2: \<0.5g/L -0.3 g/L, Grade 3: \<0.3 g/L -0.1 g/L, Grade 4: \< 0.1 g/L; IgG Grade 0: \>= LLN (7 g/L), Grade 1: \< LLN - 5 g/L, Grade 2: \<5g/L -4 g/L, Grade 3: \<4 g/L -3 g/L and Grade 4: \< 3 g/L; IgM Grade 0: \>= LLN (0.4 g/L), Grade 1: \< LLN - 0.3 g/L, Grade 2: \<0.3 g/L -0.2 g/L, Grade 3: \<0.2 g/L -0.1 g/L, and Grade 4: \< 0.1 g/L are presented in this outcome measure.
Query!
Timepoint [6]
0
0
Baseline up to Week 36
Query!
Primary outcome [7]
0
0
Number of Subjects With Positive Neutralizing Antibody (NAb)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Baseline, Week 12 and 36
Query!
Secondary outcome [1]
0
0
Number of Subjects With Clinical Attacks/Relapses
Query!
Assessment method [1]
0
0
A clinical attack/relapse was defined as the fulfillment of all the following criteria:
1. Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours.
2. Absence of fever or known infection (fever with temperature (axillary, orally, or intra-auriculary) \> 37.5°C/99.5 °Fahrenheit).
3. Objective neurological impairment, correlating with the subject's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
Query!
Timepoint [1]
0
0
Baseline up to Week 24
Query!
Secondary outcome [2]
0
0
Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 12
Query!
Assessment method [2]
0
0
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
Query!
Timepoint [2]
0
0
Baseline, Week 12
Query!
Secondary outcome [3]
0
0
Change in Multiple Sclerosis Functional Composite (MSFC) Score at Week 12
Query!
Assessment method [3]
0
0
The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).
Query!
Timepoint [3]
0
0
Week 12
Query!
Secondary outcome [4]
0
0
Magnetic Resonance Imaging (MRI) Parameters: Number of T1 Gadolinium (Gd)-Enhancing Lesions Per Subject
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline, Week 12 and 24
Query!
Secondary outcome [5]
0
0
Magnetic Resonance Imaging (MRI) Parameters: Volume of T2 Lesions (New or Enlarging T2 Lesions) Per Subject
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline, Week 12 and Week 24
Query!
Secondary outcome [6]
0
0
Concentrations of Free and Total Atacicept
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Baseline and Week 12
Query!
Secondary outcome [7]
0
0
Free B-Lymphocyte Stimulator (BLyS) and Free A Proliferation-Inducing Ligand (APRIL) Serum Concentrations.
Query!
Assessment method [7]
0
0
Levels of free APRIL and free BLyS: Free APRIL serum samples were to be analyzed by using a validated enzyme-linked immunosorbent assay (ELISA) with limits of detection of 0.3125 nanogram per milliliter (ng/mL) for free APRIL and free BlyS serum samples were analysed using a validated ELISA with limits of detection of 1.56 ng/mL.
Query!
Timepoint [7]
0
0
Baseline, Week 12 and 36
Query!
Secondary outcome [8]
0
0
Pharmacogenetics/Pharmacogenomics Analysis
Query!
Assessment method [8]
0
0
Gene expression profiling and gene polymorphism identification were to be used to identify putative markers for response to treatment.
* Genome-wide gene polymorphism characterization by genome-wide scan.
* Targeted gene polymorphism identification of B-Lymphocyte Stimulator (BLyS) , APRIL, (receptor for B cell activating factor of the tumor necrosis factor \[TNF\] family) BAFF-R, (Transmembrane Activator) TACI and (B Cell Maturation Antigen) BCMA and HLA-DRB1 by direct genotyping or sequencing .
Query!
Timepoint [8]
0
0
Day 1 and Week 36
Query!
Eligibility
Key inclusion criteria
* Participation in study 28063.
* Completion of Week 36 visit of the core study 28063.
* Willingness and ability to comply with study procedures for the duration of the study.
* Voluntary provision of written informed consent (including, for the USA, subject authorization under the Health Insurance Portability and Accountability Act (HIPAA)), given before any study-related procedure that is not part of normal medical care and with the understanding that the subject may withdraw consent at any time without prejudice to his or her future medical care.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
60
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Premature discontinuation of core study 28063.
* Subjects who meet criteria listed below will receive IMP in study 28851:
* Subjects who are eligible for participation in extension study 28851 but do not meet these criteria will not be treated with IMP but will undergo scheduled visits, irrespective of their treatment.
* All subjects must satisfy the following criteria before Extension Study Day 1 (D1-EXT; defined as the first day of dosing in the extension study) to be eligible for treatment with IMP:
* Eligibility for participation in extension study 28851.
* For women of childbearing potential, a negative urine pregnancy test at eligibility assessment.
* Female subjects of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for four (4) weeks before the first dose administered within the extension study, during the study and for twelve (12) weeks after the last dose of trial medication. Adequate contraception is defined as two barrier methods, or one barrier method with spermicide, or an intrauterine device, or use of a combined oral female hormonal contraceptive (or the definitions requested by health authorities and locally amended in the core study 28063). For the purposes of this trial, women of childbearing potential are defined as: "All female subjects after puberty unless they are post-menopausal for at least two years or are surgically sterile" (For Germany Only: Female subjects of childbearing potential must be willing to avoid pregnancy by using highly effective methods of contraception for approximately four (4) weeks prior to D1-EXT, during and for twelve (12) weeks after the last dose of trial medication. This requirement does not apply to surgically sterile subjects or to subjects who are postmenopausal for at least 2 years. Highly effective contraception is defined as any method or combination of methods which result in a low failure rate (i.e. less than (<) 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, sexual abstinence, vasectomized partner, 2 barrier methods, or 1 barrier method with spermicide)
* Willingness and ability to comply with study procedures for the duration of the study.
* To be eligible for treatment with investigational medicinal product (IMP) in study 28851, the subjects must not meet any of the following criteria:
* Non-eligibility for participation in extension study 28851 (premature discontinuation of core study 28063).
* Major protocol violation or non-compliance in the core study.
* Use of prohibited immunomodulatory / immunosuppressive therapies
* Serum immunoglobulin G (IgG) level <3 gram per liter (g/L) if the subject received atacicept in the core study, or serum IgG level <6 g/L if the subject received placebo in the core study (to protect the blinding of the core study, the IgG level will be communicated to the treating physician only if it is too low for extension study participation and only after all Week 36 assessments performed within the core study have been completed).
* Any condition, including laboratory findings that, in the opinion of the Investigator, constitutes a risk or a contraindication for participation in the extension study, or that could interfere with the study objectives, conduct or evaluation.
* Known active clinically significant acute or chronic infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives.
* Investigator judgement that treatment of the subject with atacicept in the extension study is not appropriate.
* Aspartate aminotransferase (AST), or alanine aminotransferase (ALT), or alkaline phosphatase (AP) level greater than (>)2.5 x upper limit of normal (ULN), or total bilirubin >1.5 x ULN at eligibility assessment.
* Clinically significant abnormality in any hematological test (e.g. hemoglobin <100 g/L (6.21 millimoles per liter [mmol/L]), white blood cells <3 x 10^9 per liter (/L), platelets <100 x 10^9/L) at eligibility assessment.
* Clinically significant abnormality on electrocardiogram (ECG) performed at eligibility assessment.
* Presence of uncontrolled or New York Health Association (NYHA) class 3 or 4 congestive heart failure at Week 36 of the core study.
* Moderate to severe renal impairment (creatinine clearance <50 milliliter per minute (mL/min) according to Cockcroft-Gault equation).
* Allergy or hypersensitivity to gadolinium (Gd).
* Allergy or hypersensitivity to atacicept or to any of the components of the formulated atacicept.
* Diagnosis or family history of Creutzfeldt-Jakob disease (CJD).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
74
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Box Hill VIC
Query!
Recruitment hospital [2]
0
0
Research Site - Fitzroy
Query!
Recruitment hospital [3]
0
0
Research Site - New Lambton
Query!
Recruitment hospital [4]
0
0
Research Site - Woodville
Query!
Recruitment postcode(s) [1]
0
0
- Box Hill VIC
Query!
Recruitment postcode(s) [2]
0
0
- Fitzroy
Query!
Recruitment postcode(s) [3]
0
0
- New Lambton
Query!
Recruitment postcode(s) [4]
0
0
- Woodville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Michigan
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Ohio
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Pennsylvania
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Tennessee
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Diepenbeek
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Sijsele
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Alberta
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Ontario
Query!
Country [11]
0
0
Czech Republic
Query!
State/province [11]
0
0
Brno
Query!
Country [12]
0
0
Czech Republic
Query!
State/province [12]
0
0
Hradec Králové
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Caen
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Saint-Herblain
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Bochum
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Düsseldorf
Query!
Country [17]
0
0
Lebanon
Query!
State/province [17]
0
0
Beyrouth
Query!
Country [18]
0
0
Lithuania
Query!
State/province [18]
0
0
Kaunas
Query!
Country [19]
0
0
Netherlands
Query!
State/province [19]
0
0
Breda
Query!
Country [20]
0
0
Netherlands
Query!
State/province [20]
0
0
Nieuwegein
Query!
Country [21]
0
0
Netherlands
Query!
State/province [21]
0
0
Rotterdam
Query!
Country [22]
0
0
New Caledonia
Query!
State/province [22]
0
0
Winston Salem
Query!
Country [23]
0
0
Russian Federation
Query!
State/province [23]
0
0
Ekaterinburg
Query!
Country [24]
0
0
Russian Federation
Query!
State/province [24]
0
0
Moscow
Query!
Country [25]
0
0
Russian Federation
Query!
State/province [25]
0
0
Novosibirsk
Query!
Country [26]
0
0
Russian Federation
Query!
State/province [26]
0
0
Saint Petersburg
Query!
Country [27]
0
0
Russian Federation
Query!
State/province [27]
0
0
Samara
Query!
Country [28]
0
0
Russian Federation
Query!
State/province [28]
0
0
Vladimir
Query!
Country [29]
0
0
Russian Federation
Query!
State/province [29]
0
0
Yaroslavl
Query!
Country [30]
0
0
Spain
Query!
State/province [30]
0
0
Barcelona
Query!
Country [31]
0
0
Spain
Query!
State/province [31]
0
0
Madrid
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Malaga
Query!
Country [33]
0
0
Sweden
Query!
State/province [33]
0
0
Stockholm
Query!
Country [34]
0
0
Switzerland
Query!
State/province [34]
0
0
Basel
Query!
Country [35]
0
0
Switzerland
Query!
State/province [35]
0
0
Innsbruck
Query!
Country [36]
0
0
Switzerland
Query!
State/province [36]
0
0
Zürich
Query!
Country [37]
0
0
Ukraine
Query!
State/province [37]
0
0
Kharkiv
Query!
Country [38]
0
0
Ukraine
Query!
State/province [38]
0
0
Kyiv
Query!
Country [39]
0
0
Ukraine
Query!
State/province [39]
0
0
Odessa
Query!
Country [40]
0
0
Ukraine
Query!
State/province [40]
0
0
Uzhgorod
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
London
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
Sheffield
Query!
Country [43]
0
0
United Kingdom
Query!
State/province [43]
0
0
Stoke on Trent
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
EMD Serono
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Merck KGaA, Darmstadt, Germany
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study (28851) is a long-term follow-up study of subjects enrolled in ATAMS study 28063 (NCT00642902). The aim of this study is to monitor the safety and tolerability of atacicept administered for up to 5 years to subjects with relapsing multiple sclerosis (RMS). This extension study consists of two parts. Part A will be double blind and Part B will be open label. During Part A, subjects initially randomized to atacicept will continue to receive the atacicept dose to which they have been randomized in study 28063 (ATAMS) once a week subcutaneously (under the skin). Subjects randomized to placebo in ATAMS will receive atacicept at 150 mg once a week subcutaneously during Part A. Once the results of ATAMS are available and the atacicept dose with the best benefit / risk ratio has been identified, all subjects will be switched to this dose and will continue the extension study open-label (Part B). Throughout the study, subjects and investigators will remain blinded with respect to initial and part A treatment allocation/dose.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00853762
Query!
Trial related presentations / publications
Kappos L, Hartung HP, Freedman MS, Boyko A, Radu EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014 Apr;13(4):353-63. doi: 10.1016/S1474-4422(14)70028-6. Epub 2014 Mar 6.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Daniel Mikol, MD, PhD
Query!
Address
0
0
EMD Serono
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00853762
Download to PDF